Navigation Links
Andrew Chisholm Appointed Vice President, Sales and Corporate Accounts at Accumetrics
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire/ -- Accumetrics, Inc. has appointed Andrew Chisholm to the position of Vice President, Sales and Corporate Accounts.

"Andrew brings the right mix of energy and expertise to Accumetrics. His experience will help us reach the next level in terms of our market penetration," says Timothy I. Still, President and CEO at Accumetrics. "His knowledge of the medical diagnostics industry and his relationships with distributors make him a key component of our growth strategy in 2009 and beyond."

Prior to joining Accumetrics, Mr. Chisholm served as Vice President of Sales and Corporate Accounts at Hemosense, a medical diagnostics company located in San Jose, California which was acquired by Inverness Medical in November 2007. Prior to that, Mr. Chisholm managed sales and marketing activities with increasing responsibilities at Bayer Healthcare, Henry Schein, Johnson & Johnson and the Eastman Kodak Company.

About Accumetrics (www.accumetrics.com):

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

    CONTACT:  Jules Abraham
              Lippert Heilshorn & Associates
              212-838-3777
              jabraham@lhai.com

              Timothy I. Still
              Accumetrics
              press@accumetrics.com


'/>"/>
SOURCE Accumetrics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Algeta Appoints Andrew Kay as President and Chief Executive Officer
2. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
3. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
4. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
5. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Timothy I. Still Appointed CEO at Accumetrics
8. Robert Cantu Appointed Vice President of Pierpoint International
9. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
10. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
11. Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):